# Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com

Source: https://onco.cc/trials/nct04762459/  
OnCo record `nct04762459` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of aumolertinib, pemetrexed and cisplatin in lung cancer, run by Chinese Academy of Medical Sciences, now recruiting.

## Summary

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection is a phase 3, randomised interventional study registered as NCT04762459 by Chinese Academy of Medical Sciences, with a registry enrolment figure of 606 participants, started 2021-08-01 and due to reach its primary completion in 2026-05. Interventions recorded: Almonertinib; Pemetrexed; Cisplatin. Conditions listed: Non-small Cell Lung Carcinoma. Primary outcome: Disease free survival (DFS). Lung eligibility wording from the registry: "Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: APEX
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04762459
- Phase: 3
- Setting: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for EGFR Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection: A Multicenter, Randomized Controlled, Open-label Clinical Study
- Sponsor: Chinese Academy of Medical Sciences
- Enrolled: 606

## Sources

- ClinicalTrials.gov NCT04762459: https://clinicaltrials.gov/study/NCT04762459

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04762459.json